McKesson Corporation vs Nextpower Inc. Common Stock — how do they compare? McKesson Corporation trades at $980.23 (market cap $112.15B), while Nextpower Inc. Common Stock trades at $81.37 (market cap $13.47B). The key difference: McKesson Corporation is far larger — about 8.3× Nextpower Inc. Common Stock's market cap, and McKesson Corporation pays a 0.39% dividend while Nextpower Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Nextpower Inc. Common Stock for 0 Days on average.
| MCK | NXT | |
|---|---|---|
Market Cap | $112.15B | $13.47B |
Volume | 743,618 | 2,009,302 |
Sector | Health | Energy |
52-Week High | $995.69 | $156.40 |
52-Week Low | $725.17 | $77.93 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $118.68B | $12.92B |
Dividend Yield | 0.39% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $976.57, up 2.18% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and revenue growth from $309B to $359B annually. Recent news highlights the CVS Health partnership extension through 2032, reinforcing distribution stability. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $978.
Outlook remains positive given earnings momentum and strategic partnerships, though valuation at 25.8x P/E and thin 1.12% net margins pose risks. Analysts maintain 80.65% buy ratings with $956 consensus target, slightly below current price. Key risks include drug pricing pressure and macroeconomic sensitivity. Institutional accumulation supports medium-term upside if execution continues.
NXT trades at $88.77, up 4.61% today, with strong analyst support (86% buy ratings) and a $144.67 consensus price target suggesting 63% upside. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected November 16. Revenue grew from $3.0B in 2025 to $3.6B in 2026, while maintaining robust profitability with 16.36% net margins and 27.22% ROE.
Positive outlook driven by $5.5B+ backlog and raised 2027 guidance, though rising platform investment costs and solar sector volatility present risks. Technical levels show support at $86 with resistance at $91, while valuation multiples (P/E 22.94, P/S 3.76) appear reasonable given growth trajectory.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Nextpower Inc., formerly known as Nextracker, is a solar energy technology company that designs tracking systems, structural foundations, and electrical balance-of-system equipment for utility-scale solar power plants. The company also develops software for solar yield management and is expanding into utility-scale power conversion systems.
Read more on NXT →